These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 6431630)

  • 21. Both circulating and clot-bound plasminogen activator inhibitor-1 inhibit endogenous fibrinolysis in the rat.
    Reilly CF; Fujita T; Mayer EJ; Siegfried ME
    Arterioscler Thromb; 1991; 11(5):1276-86. PubMed ID: 1911713
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Retinoic acid enhances fibrinolytic activity in-vivo by enhancing tissue type plasminogen activator (t-PA) activity and inhibits venous thrombosis.
    van Giezen JJ; Boon GI; Jansen JW; Bouma BN
    Thromb Haemost; 1993 Apr; 69(4):381-6. PubMed ID: 8497851
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Intensification of the effect of exogenous plasminogen activators on lysis of fibrin blood clots due to a decrease in the level of alpha-2- antiplasmin by a plasmasorption method].
    Ogloblina OG; Saburova OS; Semenova OA; Belova LA
    Biokhimiia; 1994 Jan; 59(1):62-8. PubMed ID: 7509643
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Binding of human tissue plasminogen activator (t-PA) to blood clots and clot-lytic activity of clot-bound t-PA.
    Kimata H; Nakajima K; Yamamoto S; Hasegawa A
    J Pharmacobiodyn; 1990 Dec; 13(12):745-50. PubMed ID: 2129127
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Whole blood clot lysis in newborns and adults after adding different concentrations of recombinant tissue plasminogen activator (Rt-PA).
    Trusen B; Ries M; Zenker M; Rauh M; Beinder E; Keuper H; Harms D
    Semin Thromb Hemost; 1998; 24(6):599-604. PubMed ID: 10066156
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of fibrin-targeting on clot lysis with urokinase-type plasminogen activator.
    Lijnen HR; Dewerchin M; De Cock F; Collen D
    Thromb Res; 1990 Feb; 57(3):333-42. PubMed ID: 2107593
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A direct oral anticoagulant edoxaban accelerated fibrinolysis via enhancement of plasmin generation in human plasma: dependent on thrombin-activatable fibrinolysis inhibitor.
    Morishima Y; Honda Y
    J Thromb Thrombolysis; 2019 Jul; 48(1):103-110. PubMed ID: 30972711
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Biological and thrombolytic properties of proenzyme and active forms of human urokinase--IV. Variability in fibrinolytic response of plasma of several mammalian species.
    Lijnen HR; De Wreede K; Demarsin E; Collen D
    Thromb Haemost; 1984 Aug; 52(1):31-3. PubMed ID: 6495261
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The roles of alpha 2-antiplasmin and plasminogen activator inhibitor 1 (PAI-1) in the inhibition of clot lysis.
    Robbie LA; Booth NA; Croll AM; Bennett B
    Thromb Haemost; 1993 Aug; 70(2):301-6. PubMed ID: 8236139
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of standard heparin and a low molecular weight heparin on thrombolytic and fibrinolytic activity of single-chain urokinase plasminogen activator in vitro.
    Lourenço DM; Dosne AM; Kher A; Samama M
    Thromb Haemost; 1989 Nov; 62(3):923-6. PubMed ID: 2556812
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of clot lysis and decreased binding of tissue-type plasminogen activator as a consequence of clot retraction.
    Kunitada S; FitzGerald GA; Fitzgerald DJ
    Blood; 1992 Mar; 79(6):1420-7. PubMed ID: 1547340
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Influence of the fast-acting inhibitor of plasminogen activator on in vivo thrombolysis induced by tissue-type plasminogen activator in rabbits. Interference of tissue-derived components.
    Colucci M; Paramo JA; Stassen JM; Collen D
    J Clin Invest; 1986 Jul; 78(1):138-44. PubMed ID: 3088040
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Alpha 2-antiplasmin supplementation inhibits tissue plasminogen activator-induced fibrinogenolysis and bleeding with little effect on thrombolysis.
    Weitz JI; Leslie B; Hirsh J; Klement P
    J Clin Invest; 1993 Apr; 91(4):1343-50. PubMed ID: 7682569
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Age-related differences in a clot lysis assay after adding different plasminogen activators in a plasma milieu in vitro.
    Ries M; Zenker M; Klinge J; Keuper H; Harms D
    J Pediatr Hematol Oncol; 1995 Aug; 17(3):260-4. PubMed ID: 7620925
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibition of one-chain and two-chain forms of human tissue-type plasminogen activator by the fast-acting inhibitor of plasminogen activator in vitro and in vivo.
    Colucci M; Paramo JA; Collen D
    J Lab Clin Med; 1986 Jul; 108(1):53-9. PubMed ID: 3086473
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Plasminogen activator inhibitor-1 suppresses endogenous fibrinolysis in a canine model of pulmonary embolism.
    Reilly CF; Fujita T; Hutzelmann JE; Mayer EJ; Shebuski RJ
    Circulation; 1991 Jul; 84(1):287-92. PubMed ID: 1905594
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Thrombolytic profiles of clot-targeted plasminogen activators. Parameters determining potency and initial and maximal rates.
    Holvoet P; Dewerchin M; Stassen JM; Lijnen HR; Tollenaere T; Gaffney PJ; Collen D
    Circulation; 1993 Mar; 87(3):1007-16. PubMed ID: 8443877
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prevention of coronary thrombosis with subthrombolytic doses of tissue-type plasminogen activator.
    Fox KA; Robison AK; Knabb RM; Rosamond TL; Sobel BE; Bergmann SR
    Circulation; 1985 Dec; 72(6):1346-54. PubMed ID: 3933849
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of low molecular weight heparins on fibrin polymerization and clot sensitivity to t-PA-induced lysis.
    Parise P; Morini M; Agnelli G; Ascani A; Nenci GG
    Blood Coagul Fibrinolysis; 1993 Oct; 4(5):721-7. PubMed ID: 8292721
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interactions of tissue-type plasminogen activator with plasma inhibitors and their pharmacologic implications.
    Lucore CL; Sobel BE
    Circulation; 1988 Mar; 77(3):660-9. PubMed ID: 2449299
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.